A Compensatory Mutation Provides Resistance to Disparate HIV Fusion Inhibitor Peptides and Enhances Membrane Fusion

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Wood, Matthew P ^a   Cole, Amy L ^a   Ruchala, Piotr ^b   Waring, Alan J ^b   Rohan, Lisa C ^c,d   Marx, Preston ^e   Tarwater, Patrick M ^f   Gupta, Phalguni ^c   Cole, Alexander M ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^f TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; RC 101; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; ENVELOPE GENE; MEMBRANE FUSION; MUTANT; MUTATIONAL ANALYSIS; NONHUMAN; PROTEIN FUNCTION; SEQUENCE ANALYSIS; VIRUS ENTRY; VIRUS REPLICATION; WILD TYPE;

CELL LINE; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HUMANS; MEMBRANE FUSION; MUTATION; PEPTIDES;

EID: 84873508451     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055478     Document Type: Article

References (32)

1. Melikyan G, Markosyan R, Hemmati H, Delmedico M, Lambert D, et al. (2000) Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 151: 413-423.
2. Chan D, Fass D, Berger J, Kim P, (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89: 263-273.
3. Gallo S, Wang W, Rawat S, Jung G, Waring A, et al. (2006) Theta-defensins prevent HIV-1 env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem 281: 18787-18792.
4. He Y, Vassell R, Zaitseva M, Nguyen N, Yang Z, et al. (2003) Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J Virol 77: 1666-1671.
5. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ, (1994) Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 91: 9770-9774.
6. Poveda E, Rodes B, Labernardiere JL, Benito JM, Toro C, et al. (2004) Evolution of genotypic and phenotypic resistance to enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol 74: 21-28.
7. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896-19050.
8. Fuhrman C, Warren A, Waring A, Dutz S, Sharma S, et al. (2007) Retrocyclin RC-101 overcomes cationic mutations on the heptad repeat 2 region of HIV-1 gp41. FEBS J 274: 6477-6487.
9. Cole A, Yang O, Warren A, Waring A, Lehrer R, et al. (2006) HIV-1 adapts to a retrocyclin with cationic amino acid substitutions that reduce fusion efficiency of gp41. J Immunol 176: 6900-6905.
10. Owen S, Rudolph D, Wang W, Cole A, Waring A, et al. (2004) RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates. AIDS Res Hum Retroviruses 20: 1157-1165.
11. Cole A, Herasimtschuk A, Gupta P, Waring A, Lehrer R, et al. (2007) The retrocyclin analogue RC-101 prevents human immunodeficiency virus type 1 infection of a model human cervicovaginal tissue construct. Immunology 121: 140-145.
12. Cole A, Patton D, Rohan L, Cole A, Cosgrove-Sweeney Y, et al. (2010) The formulated microbicide RC-101 was safe and antivirally active following intravaginal application in pigtailed macaques. PLoS ONE 5: e15111.
13. Cole AM, Hong T, Boo LM, Nguyen T, Zhao C, et al. (2002) Retrocyclin: A primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc Natl Acad Sci U S A 99: 1813-1818.
14. Eade CR, Wood MP, Cole AM, (2012) Mechanisms and modifications of naturally occurring host defense peptides for anti-HIV microbicide development. Curr HIV Res 10: 61-72.
15. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, et al. (1986) Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59: 284-291.
16. Lamers RP, Eade CR, Waring AJ, Cole AL, Cole AM, (2011) Characterization of the retrocyclin analogue RC-101 as a preventative of staphylococcus aureus nasal colonization. Antimicrob Agents Chemother 55: 5338-5346.
17. Fields GB, Noble RL, (1990) Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 35: 161-214.
18. Micewicz E, Cole A, Jung C, Luong H, Phillips M, et al. (2010) Grifonin-1: A small HIV-1 entry inhibitor derived from the algal lectin, griffithsin. PLoS ONE 5: e14360.
19. Kimpton J, Emerman M, (1992) Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 66: 2232-2239.
20. Reed LJ, Muench H, (1938) A simple method for estimating fifty percent endpoints. Am J Hygiene 27: 493-497.
21. Miyauchi K, Kozlov MM, Melikyan GB, (2009) Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation. PLoS Pathog 5: e1000585.
22. Barrio AM, Lagercrantz E, Sperber GO, Blomberg J, Bongcam-Rudloff E, (2009) Annotation and visualization of endogenous retroviral sequences using the distributed annotation system (DAS) and eBioX. BMC Bioinformatics 10Suppl 6: S18.
23. Baldwin C, Berkhout B, (2008) Mechanistic studies of a T20-dependent human immunodeficiency virus type 1 variant. J Virol 82: 7735-7740.
24. Baldwin C, Sanders R, Deng Y, Jurriaans S, Lange J, et al. (2004) Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol 78: 12428-12437.
25. Caffrey M, (2001) Model for the structure of the HIV gp41 ectodomain: Insight into the intermolecular interactions of the gp41 loop. Biochim Biophys Acta 1536: 116-122.
26. Chang T, Vargas J, DelPortillo A, Klotman M, (2005) Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest 115: 765-773.
27. Furci L, Sironi F, Tolazzi M, Vassena L, Lusso P, (2007) Alpha-defensins block the early steps of HIV-1 infection: Interference with the binding of gp120 to CD4. Blood 109: 2928-2935.
28. Trivedi VD, Cheng SF, Wu CW, Karthikeyan R, Chen CJ, et al. (2003) The LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20. Protein Eng 16: 311-317.
29. Eggink D, Baldwin CE, Deng Y, Langedijk JP, Lu M, et al. (2008) Selection of T1249-resistant human immunodeficiency virus type 1 variants. J Virol 82: 6678-6688.
30. Liu Z, Shan M, Li L, Lu L, Meng S, et al. (2011) In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor. J.Biol.Chem. 286: 3277-3287.
31. Ray N, Blackburn L, Doms R, (2009) HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide. J Virol 83: 2989-2995.
32. Reeves J, Gallo S, Ahmad N, Miamidian J, Harvey P, et al. (2002) Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A 99: 16249-16254.